D&D Pharmatech Inc. (KOSDAQ:347850)
South Korea flag South Korea · Delayed Price · Currency is KRW
51,800
-1,700 (-3.18%)
Sep 1, 2026, 3:30 PM KST

D&D Pharmatech Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-23,200-23,555-28,6233,934-136,067-68,224
Depreciation & Amortization
5,5145,5315,5274,42813,73911,901
Loss (Gain) From Sale of Assets
22.040.13118.3884.78-21,524-
Asset Writedown & Restructuring Costs
--9,199-4,582119,722-
Loss (Gain) on Equity Investments
5,0454,815-1,8391,7879,148-
Stock-Based Compensation
2,3121,472762.942,8434,0575,576
Other Operating Activities
-12,220-11,327-1,510-15,025-39,488-7,399
Change in Accounts Receivable
251.253,985-3,921-3,618-231.5897.49
Change in Other Net Operating Assets
-2,622-2,061-1,5191,030-2,4395,304
Operating Cash Flow
-24,899-21,139-21,805-9,117-53,083-51,945
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-36.59-64.41-395.75-45.22-711.88-1,615
Sale of Property, Plant & Equipment
--8.87323.21240.02-
Sale (Purchase) of Intangibles
---20--7.03-603.83
Other Investing Activities
-42.59-25.84-132.64-9.84-263.02
Investing Cash Flow
-79.18-90.25-539.53268.14-478.89-1,955

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
---1,0003,2176,329
Total Debt Issued
---1,0003,2176,329
Short-Term Debt Repaid
--925.12----
Long-Term Debt Repaid
--1,843-1,730-1,625-1,378-774.99
Total Debt Repaid
-1,880-2,769-1,730-1,625-1,378-774.99
Net Debt Issued (Repaid)
-1,880-2,769-1,730-625.251,8395,554
Issuance of Common Stock
6,1377,38237,980-1473,014
Other Financing Activities
19,58119,581-0-4.67-0-0
Financing Cash Flow
23,83824,19536,251-629.921,98667,692

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-433.3-95.36465.06-382.51,1231,554
Net Cash Flow
-1,5742,87014,372-9,862-50,45415,346

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-24,935-21,203-22,201-9,163-53,795-53,560
Free Cash Flow Growth
------
Free Cash Flow Margin
-827.62%-493.38%-194.12%-49.06%-8810.69%-3926.36%
Free Cash Flow Per Share
-575.14-482.64-547.42-244.19-1668.57-1627.16
Levered Free Cash Flow
-32,457-27,099-13,079-28,427-29,052-14,039
Unlevered Free Cash Flow
-32,207-26,805-12,695-27,535-27,203-13,407

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
374.34396.9400.26454.26510.72247.05
Cash Income Tax Paid
--22.7455.41,89683.39354.64
Change in Working Capital
-2,3711,925-5,440-2,587-2,6706,201